

Consensus: Evidence for Autism Diets Lacking

BY ROBERT FINN

There's no good evidence that children with autism have unique gastrointestinal disorders, nor is there convincing evidence that gluten-free or casein-free diets help these children, according to an expert panel.

The panel, convened by the Autism Forum, reached consensus on 23 statements regarding the evaluation, diagnosis, and treatment of gastrointestinal disorders in children with autism spectrum disorders (ASDs) (Pediatrics 2010;125:S1-S18).

One key recommendation was that children with ASDs need to be evaluated carefully for GI problems because many such children are nonverbal, and even those who are verbal may have difficulty describing their symptoms, such as abdominal pain.

In particular, the panel noted that children with ASDs often respond to GI symptoms by exhibiting problem be-

Children with autism spectrum disorders need to be evaluated carefully for GI problems because many such children are nonverbal.

haviors such as agitation, aggression, and sleep disturbances.

The panel included experts in child psychiatry, developmental pediatrics, epidemiology, medical genetics, immunology, nursing, pediatric allergy, pediatric gastroenterology, pediatric pain, pediatric neurology, pediatric nutrition, and psychology. Dr. Timothy Buie of Harvard Medical School, Boston, was the paper's lead author.

The recommendations were based on a literature review, but without a formal meta-analysis. "Because of the absence, in general, of high-quality clinical research data, evidence-based recommendations are not possible at the present time," the panelists wrote. "However, the panel agreed on a number of statements based on expert opinion that arose from a review of existing evidence. It is acknowledged that, in many areas, evidence is generally con-

finned to case reports, observational or descriptive studies, and poorly controlled or uncontrolled studies."

Among the panel's other conclusions were:

► Children with ASDs are subject to the same common GI disorders as neurotypical children and should be evaluated thoroughly. In particular, clinicians should be sure that these children receive a complete medical evaluation for GI dis-

orders when they present with problem behaviors. Behavioral treatment may complement medical treatment in children with both ASDs and GI disorders, but behavioral treatment alone is not enough.

► The existence of "autistic enterocolitis" or other gastrointestinal disturbances unique to children with ASDs has not been established, and the evidence for abnormal gastrointestinal per-

meability ("leaky gut") is limited. More research is needed in these areas, the panel said.

► Pediatricians and other primary care providers should be alert to nutritional problems in children with ASDs. Some of these children have narrow food preferences, and some parents may put their children on highly restrictive diets that are intended to be therapeutic but result in malnutrition. ■



Model is for illustrative purposes only.

Indications and usage

Levemir® is indicated for once- or twice-daily subcutaneous administration for the treatment of adult and pediatric patients with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia.

Important safety information

Levemir® is contraindicated in patients hypersensitive to insulin detemir or one of its excipients.

Hypoglycemia is the most common adverse effect of all insulin therapies, including Levemir®. As with other insulins, the timing of hypoglycemic events may differ among various insulin preparations. Glucose monitoring is recommended for all patients with diabetes. Levemir® is not to be used in insulin infusion pumps. Any change of insulin dose should be made cautiously and only under medical supervision. Concomitant oral antidiabetes treatment may require adjustment.

Inadequate dosing or discontinuation of treatment may lead to hyperglycemia and, in patients with type 1 diabetes, diabetic ketoacidosis. Levemir® should not be diluted or mixed with any

other insulin preparations. Insulin may cause sodium retention and edema, particularly if previously poor metabolic control is improved by intensified insulin therapy. Dose and timing of administration may need to be adjusted to reduce the risk of hypoglycemia in patients being switched to Levemir® from other intermediate or long-acting insulin preparations. The dose of Levemir® may need to be adjusted in patients with renal or hepatic impairment.

Other adverse events commonly associated with insulin therapy may include injection site reactions (on average, 3% to 4% of patients in clinical trials) such as lipodystrophy, redness, pain, itching, hives, swelling, and inflammation.

*Whether these observed differences represent true differences in the effects of Levemir®, NPH insulin, and insulin glargine is not known, since these trials were not blinded and the protocols (eg, diet and exercise instructions and monitoring) were not specifically directed at exploring hypotheses related to weight effects of the treatments compared. The clinical significance of the observed differences in weight has not been established.

For your patients with type 2 diabetes, start once-daily Levemir®

Levemir® helps patients with diabetes achieve their A1C goal.^{2,3}

- 24-hour action at a once-daily dose^{4,5}
- Provides consistent insulin absorption and action, day after day^{4,6,7}
- Less weight gain^{8*}

To access complimentary e-learning programs, visit novomedlink.com/Levemir

References: 1. Data on file. Novo Nordisk Inc, Princeton, NJ. 2. Meneghini LF, Rosenberg KH, Koenen C, Meriläinen MJ, Lüdtke H-J. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. *Diabetes Obes Metab*. 2007;9(3):418-427. 3. Hermansen K, Davies M, Derezinski T, Ravn GM, Clauson P, Home P, for the Levemir Treat-to-Target Study Group. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetes. *Diabetes Care*. 2006;29(6):1269-1274. 4. Klein O, Lyngø J, Endahl L, Damholt B, Nosek L, Heise T. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. *Diabetes Obes Metab*. 2007;9(3):290-299. 5. Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. *Clin Ther*. 2006;28(10):1569-1581. 6. Danne T, Endahl L, Haahr H, et al. Lower within-subject variability in pharmacokinetic profiles of insulin detemir in comparison to insulin glargine in children and adolescents with type 1 diabetes. Presented at: 43rd Annual Meeting of the European Association for the Study of Diabetes; September 17-21, 2007; Amsterdam, Netherlands. Abstract 0189. 7. Heise T, Nosek L, Rønn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. *Diabetes*. 2004;53(6):1614-1620. 8. Data on file. NDA21-536. Novo Nordisk Inc, Princeton, NJ.



Please see brief summary of Prescribing Information on adjacent page.

FlexPen® and Levemir® are registered trademarks of Novo Nordisk A/S.
© 2008 Novo Nordisk Inc. 133236-R2 November 2008



Major Finding: Children with autism spectrum disorders need careful GI evaluations, but there's no good evidence that they have unique gastrointestinal problems or benefit from restricted diets.

Data Source: Literature review and the consensus of an interdisciplinary expert panel

Disclosures: The Autism Forum convened the panel and provided honoraria to its 14 members. One panel member reported relationships with a number of pharmaceutical companies. Another chairs an academic department that derives revenue from genetic laboratory testing.